Journal Watch · Journal of Medicinal Chemistry · 2026
Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors.
Here, we describe the structure- and property-based design of reversible inhibitors of diverse oncogenic mutants of KRAS, leading to <b>AM-2383</b>, a pan-KRAS inhibitor that blocks signaling via both the GDP(off)- and GTP(on)-bound states of KRAS, while sparing the closely related RAS isoforms HRAS and NRAS. <b>AM-2383</b> disrupts signaling downstream of KRAS, potently suppressing the growth of <i>KRAS</i><sup>G12D</sup> and <i>KRAS</i><sup>G12V</sup> tumor xenografts following oral administration. <b>AM-2383</b> represents an important proof-of-concept that structural insights from prior covalent KRAS<sup>G12C</sup> inhibitors can be leveraged in the design of efficacious and well-tolerated inhibitors of diverse <i>KRAS</i> mutations.
TL;DR
Here, we describe the structure- and property-based design of reversible inhibitors of diverse oncogenic mutants of KRAS, leading to <b>AM-2383</b>, a pan-KRAS inhibitor that blocks signaling via both the GDP(off)- and GTP(on)-bound states of KRAS, while sparing the closely related RAS isoforms HRAS and NRAS. <b>AM-2383</b> disrupts signaling downstream of KRAS, potently suppressing the growth of <i>KRAS</i><sup>G12D</sup> and <i>KRAS</i><sup>G12V</sup> tumor xenografts following oral administration. <b>AM-2383</b> represents an important proof-of-concept that structural insights from prior covalent KRAS<sup>G12C</sup> inhibitors can be leveraged in the design of efficacious and well-tolerated inhibitors of diverse <i>KRAS</i> mutations.
Key findings
- The approval of covalent KRAS<sup>G12C</sup> inhibitors, such as sotorasib and adagrasib, has fueled intense interest in expanding KRAS-directed therapies to mutations beyond <i>KRAS</i><sup>G12C</sup>, such as <i>KRAS</i><sup>G12D</sup>, <i>KRAS</i><sup>G12V</sup>, and <i>KRAS</i><sup>G13D</sup>.
- Here, we describe the structure- and property-based design of reversible inhibitors of diverse oncogenic mutants of KRAS, leading to <b>AM-2383</b>, a pan-KRAS inhibitor that blocks signaling via both the GDP(off)- and GTP(on)-bound states of KRAS, while sparing the closely related RAS isoforms HRAS and NRAS. <b>AM-2383</b> disrupts signaling downstream of KRAS, potently suppressing the growth of <i>KRAS</i><sup>G12D</sup> and <i>KRAS</i><sup>G12V</sup> tumor xenografts following oral administration. <b>AM-2383</b> represents an important proof-of-concept that structural insights from prior covalent KRAS<sup>G12C</sup> inhibitors can be leveraged in the design of efficacious and well-tolerated inhibitors of diverse <i>KRAS</i> mutations.
What they did
Therapeutically targeting mutant KRAS represents a clinically validated approach for the treatment of solid tumors, including lung, colon, and pancreatic cancers.
Full abstract (original)
Abstract: Therapeutically targeting mutant KRAS represents a clinically validated approach for the treatment of solid tumors, including lung, colon, and pancreatic cancers. The approval of covalent KRAS<sup>G12C</sup> inhibitors, such as sotorasib and adagrasib, has fueled intense interest in expanding KRAS-directed therapies to mutations beyond <i>KRAS</i><sup>G12C</sup>, such as <i>KRAS</i><sup>G12D</sup>, <i>KRAS</i><sup>G12V</sup>, and <i>KRAS</i><sup>G13D</sup>. Here, we describe the structure- and property-based design of reversible inhibitors of diverse oncogenic mutants of KRAS, leading to <b>AM-2383</b>, a pan-KRAS inhibitor that blocks signaling via both the GDP(off)- and GTP(on)-bound states of KRAS, while sparing the closely related RAS isoforms HRAS and NRAS. <b>AM-2383</b> disrupts signaling downstream of KRAS, potently suppressing the growth of <i>KRAS</i><sup>G12D</sup> and <i>KRAS</i><sup>G12V</sup> tumor xenografts following oral administration. <b>AM-2383</b> represents an important proof-of-concept that structural insights from prior covalent KRAS<sup>G12C</sup> inhibitors can be leveraged in the design of efficacious and well-tolerated inhibitors of diverse <i>KRAS</i> mutations.
Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.6c01325 · PubMed 42446418.
Why it matters for pharma & biotech
- Directly relevant to teams in targeted oncology / immuno-oncology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: targeted oncology / immuno-oncology · small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Journal of Medicinal Chemistry study find?
Here, we describe the structure- and property-based design of reversible inhibitors of diverse oncogenic mutants of KRAS, leading to <b>AM-2383</b>, a pan-KRAS inhibitor that blocks signaling via both the GDP(off)- and GTP(on)-bound states of KRAS, while sparing the closely related RAS isoforms HRAS and NRAS. <b>AM-2383</b> disrupts signaling downstream of KRAS, potently suppressing the growth of <i>KRAS</i><sup>G12D</sup> and <i>KRAS</i><sup>G12V</sup> tumor xenografts following oral administration. <b>AM-2383</b> represents an important proof-of-concept that structural insights from prior covalent KRAS<sup>G12C</sup> inhibitors can be leveraged in the design of efficacious and well-tolerated inhibitors of diverse <i>KRAS</i> mutations.
What type of study is this?
It is a preclinical (animal / model) study, published in Journal of Medicinal Chemistry in 2026. Therapeutically targeting mutant KRAS represents a clinically validated approach for the treatment of solid tumors, including lung, colon, and pancreatic cancers.
Where can I read the original paper?
The original is at the publisher via DOI 10.1021/acs.jmedchem.6c01325. PubMed ID: 42446418. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/expanding-addressable-kras-mutations-through-the-structure-and-property-c01325/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides